Rituximab Treatment in Sjogren's Syndrome
NCT00363350
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Sjogren's Syndrome
Interventions
DRUG:
rituximab (anti-CD20)
Sponsor
University Medical Center Groningen
Collaborators
[object Object]